Markus Reindl1, Sven Jarius, Kevin Rostasy, Thomas Berger. 1. aClinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Tyrol, Austria bMolecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Heidelberg cDepartment of Pediatric Neurology, Vestische Kinder- und Jugendklinik Datteln, University Witten/Herdecke, Datteln, Germany.
Abstract
PURPOSE OF REVIEW: Serum IgG autoantibodies against the myelin oligodendrocyte glycoprotein (MOG) are present in atypical demyelinating disorders such as neuromyelitis optica spectrum disorders (NMOSD) or acute disseminated encephalomyelitis. Whereas the role of aquaporin-4 antibodies as diagnostic markers for NMOSD is meanwhile well established, the role of MOG antibodies is less clear. RECENT FINDINGS: Initial studies suggested that MOG antibodies are associated with a more benign disease course than aquaporin-4antibodies. However, recent findings challenged this view. Data from the two largest cohorts of adult MOG antibody-positive patients with the longest clinical follow-up published so far indicate that the majority of patients develop a recurrent disease course with optic neuritis as the most frequent symptom, particularly in women. Frequent attacks are often associated with accumulating damage and functional impairment. The clinical spectrum of acquired demyelinating syndromes associated with MOG antibodies seems to be broader as anticipated in prior studies, with only a third of patients fulfilling the current diagnostic criteria for NMOSD. SUMMARY: MOG antibodies are associated with an increasing spectrum of age and sex-dependent clinical phenotypes, only partly overlapping with NMOSD and multiple sclerosis and with a high risk of a recurrent disease course.
PURPOSE OF REVIEW: Serum IgG autoantibodies against the myelin oligodendrocyte glycoprotein (MOG) are present in atypical demyelinating disorders such as neuromyelitis optica spectrum disorders (NMOSD) or acute disseminated encephalomyelitis. Whereas the role of aquaporin-4 antibodies as diagnostic markers for NMOSD is meanwhile well established, the role of MOG antibodies is less clear. RECENT FINDINGS: Initial studies suggested that MOG antibodies are associated with a more benign disease course than aquaporin-4antibodies. However, recent findings challenged this view. Data from the two largest cohorts of adult MOG antibody-positive patients with the longest clinical follow-up published so far indicate that the majority of patients develop a recurrent disease course with optic neuritis as the most frequent symptom, particularly in women. Frequent attacks are often associated with accumulating damage and functional impairment. The clinical spectrum of acquired demyelinating syndromes associated with MOG antibodies seems to be broader as anticipated in prior studies, with only a third of patients fulfilling the current diagnostic criteria for NMOSD. SUMMARY:MOG antibodies are associated with an increasing spectrum of age and sex-dependent clinical phenotypes, only partly overlapping with NMOSD and multiple sclerosis and with a high risk of a recurrent disease course.
Authors: Yael Hacohen; Yu Yi Wong; Christian Lechner; Maciej Jurynczyk; Sukhvir Wright; Bahadir Konuskan; Judith Kalser; Anne Lise Poulat; Helene Maurey; Esther Ganelin-Cohen; Evangeline Wassmer; Chery Hemingway; Rob Forsyth; Eva Maria Hennes; M Isabel Leite; Olga Ciccarelli; Banu Anlar; Rogier Hintzen; Romain Marignier; Jacqueline Palace; Matthias Baumann; Kevin Rostásy; Rinze Neuteboom; Kumaran Deiva; Ming Lim Journal: JAMA Neurol Date: 2018-04-01 Impact factor: 18.302
Authors: S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann Journal: Nervenarzt Date: 2018-12 Impact factor: 1.214
Authors: John J Chen; Elias S Sotirchos; Amanda D Henderson; Eleni S Vasileiou; Eoin P Flanagan; M Tariq Bhatti; Sepideh Jamali; Eric R Eggenberger; Marie Dinome; Larry P Frohman; Anthony C Arnold; Laura Bonelli; Nicolas Seleme; Alvaro J Mejia-Vergara; Heather E Moss; Tanyatuth Padungkiatsagul; Hadas Stiebel-Kalish; Itay Lotan; Mark A Hellmann; Dave Hodge; Frederike Cosima Oertel; Friedemann Paul; Shiv Saidha; Peter A Calabresi; Sean J Pittock Journal: Mult Scler Relat Disord Date: 2022-01-11 Impact factor: 4.339
Authors: John J Chen; Eoin P Flanagan; M Tariq Bhatti; Jiraporn Jitprapaikulsan; Divyanshu Dubey; Alfonso Sebastian S Lopez Chiriboga; James P Fryer; Brian G Weinshenker; Andrew McKeon; Jan-Mendelt Tillema; Vanda A Lennon; Claudia F Lucchinetti; Amy Kunchok; Collin M McClelland; Michael S Lee; Jeffrey L Bennett; Victoria S Pelak; Gregory Van Stavern; Ore-Ofe O Adesina; Eric R Eggenberger; Marie D Acierno; Dean M Wingerchuk; Byron L Lam; Heather Moss; Shannon Beres; Aubrey L Gilbert; Veeral Shah; Grayson Armstrong; Gena Heidary; Dean M Cestari; Hadas Stiebel-Kalish; Sean J Pittock Journal: Neurology Date: 2020-06-17 Impact factor: 11.800